|1.||Mammen, Andrew L: 5 articles (06/2015 - 03/2011)|
|2.||Inoue, Masahiro: 4 articles (07/2006 - 02/2002)|
|3.||Kusama, Toshiyuki: 4 articles (07/2006 - 02/2002)|
|4.||Tatsuta, Masaharu: 4 articles (07/2006 - 02/2002)|
|5.||Nakamura, Hiroyuki: 4 articles (07/2006 - 02/2002)|
|6.||Mukai, Mutsuko: 4 articles (07/2006 - 02/2002)|
|7.||Golab, Jakub: 3 articles (07/2011 - 10/2003)|
|8.||Tounai, Hiroko: 3 articles (03/2007 - 11/2005)|
|9.||Hayakawa, Natsumi: 3 articles (03/2007 - 11/2005)|
|10.||Araki, Tsutomu: 3 articles (03/2007 - 11/2005)|
01/01/2009 - "HMG-CoA inhibitors (statins) are widely used for the prevention of cardiovascular events and the management of hypercholesterolemia. "
03/02/2015 - "As inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase, statins are an important first-line treatment for hypercholesterolemia. "
04/01/1982 - "These results suggest that if long-term safety can be demonstrated, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase are likely to prove useful in the treatment of hypercholesterolemia."
04/01/2015 - "Statins [hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitors] are widely prescribed drugs in hypercholesterolemia. "
04/01/2014 - "Statins, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, are widely prescribed for hypercholesterolemia. "
|2.||Cardiovascular Diseases (Cardiovascular Disease)
06/01/2007 - "Whether used as primary or secondary prevention, 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) can lead to a significant reduction in mortality and morbidity from cardiovascular disease. "
12/01/2010 - "Clinical trials of lipid-lowering 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) have shown improved cardiovascular outcomes; therefore, statins have become a mainstay in the prevention of cardiovascular disease. "
05/01/2015 - "Lipid lowering, particularly with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors ("statins"), reduces the risk of cardiovascular disease. "
03/01/2014 - "3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) have been proved highly effective treatments for primary and secondary prevention of cardiovascular diseases. "
01/01/2014 - "Statins are enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors that have been included in the therapeutic regimen of cardiovascular diseases due to their lipid-lowering activity. "
09/01/2013 - "3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) are the first-line pharmaceuticals for the prevention and treatment of dyslipidemia. "
04/01/2008 - "The primary role of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) is to treat dyslipidemia. "
08/01/2007 - "The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) are the cornerstone of therapy for dyslipidemia. "
09/01/2010 - "Statins act on the rate-limiting step in cholesterol biosynthesis (the conversion of HMG-CoA to mevalonate) and are effective in treating dyslipidemia. "
12/01/2014 - "Statins, 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors are commonly used drugs in the treatment of dyslipidemias, primarily raised cholesterol. "
09/01/2014 - "Lovastatin showed decreased fibrosis on histopathology and improved survival at day 14, with a decrease in fibrocytes noted at day 8. Lovastatin and LFA 878 inhibit LMW HA inflammatory signaling independent of HMG-CoA decreasing the chemotactic cytokine MIP 1-α. "
08/01/2012 - "3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor simvastatin ameliorates renal fibrosis through HOXA13-USAG-1 pathway."
01/15/2010 - "ACE inhibitors, Angiotensin Receptor Blockers, and HMG-CoA inhibitors merit further investigation in CD because of their role in preventing fibrosis in cardiovascular and renal diseases. "
12/18/2013 - "Statins are inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase in cholesterol biosynthesis, and they have been reported to exert pleiotropic effects on the cellular signaling involved in tissue inflammation and in organ fibrosis/remodeling. "
08/01/2001 - "It was supposed that inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG CoA) reductase (statins) might inhibit the expression of the fibrosis-related factor CTGF (connective tissue growth factor) by interfering with the isoprenylation of Rho proteins. "
|5.||Muscular Diseases (Myopathy)
06/01/2004 - "The initial trials, which assessed the efficacy of first-generation HMG-CoA inhibitors, did not show a clinically significant increase in the incidence of myopathy. "
04/01/2014 - "The HMG-CoA-R clinical active site inhibitors (statins) are among the most widespread and profitable drugs ever sold but their side effects (myopathies, sometimes severe) still limit their use, which makes the finding of alternatives to statins a field of intense research. "
09/01/1998 - "A combination of electrophysiological, pathological, and biochemical studies were performed in myopathy induced by 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors. "
08/01/2015 - "To analyze clinical features and myopathology changes in muscle fibers, connective tissue, and vessels in 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) antibody-associated myopathies. "
06/01/2015 - "We examined a cohort of Australian patients with statin exposure who developed a necrotizing autoimmune myopathy (NAM) associated with a novel autoantibody against 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) and describe the clinical and therapeutic challenges of managing these patients and an optimal therapeutic strategy. "
|2.||Hydroxymethylglutaryl CoA Reductases (HMG CoA Reductase)
|6.||Mevalonic Acid (Mevalonate)
|7.||Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)
|8.||Coenzyme A (CoA)
|3.||Transplantation (Transplant Recipients)
|4.||Drug Therapy (Chemotherapy)
|5.||Photochemotherapy (Photodynamic Therapy)